LY2584702 Clinical Trials

Size	Price	Qty
5mg	USD 147
25mg	USD 447

Clinical Trials

Multiple clinical trials sponsored by Eli Lilly and Company have evaluated LY2584702 as a monotherapy or in combination with targeted therapies like erlotinib or everolimus in Phase I and Phase Ib settings. These studies targeted healthy participants and patients with advanced or metastatic solid tumors, non-small cell lung carcinoma, renal cell carcinoma, or neuroendocrine tumors to assess safety, pharmacokinetics, and preliminary efficacy. Recruitment across these early-phase trials has concluded, with final trial statuses documented as either completed or terminated.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01241461	COMPLETED	Cancer	Eli Lilly and Company	2010-11	PHASE1
NCT01372085	COMPLETED	Healthy Participants	Eli Lilly and Company	2011-06	PHASE1
NCT01115803	TERMINATED	Metastases, Neoplasm; Carcinoma, Non-small Cell Lung; Renal Cell Carcinoma; Neuroendocrine Tumors	Eli Lilly and Company	2010-03	PHASE1
NCT01394003	TERMINATED	Advanced Cancer	Eli Lilly and Company	2008-11	PHASE1
NCT01241461	Completed	Cancer	Eli Lilly and Company	2010-11	Phase 1
NCT01115803	Terminated	Metastases Neoplasm\|Carcinoma Non-small Cell Lung\|Renal Cell Carcinoma\|Neuroendocrine Tumors	Eli Lilly and Company	2010-03	Phase 1
NCT01394003	Terminated	Advanced Cancer	Eli Lilly and Company	2008-11	Phase 1

(data from https://clinicaltrials.gov, updated on 2018-08-21)

Check the LY2584702 product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

LY2584702 functions as a selective, ATP-competitive inhibitor of p70S6K, binding to the kinase domain to block downstream ribosomal protein S6 phosphorylation and disrupt protein translation cascades essential for cellular proliferation. By suppressing this signaling axis, the compound impairs tumor cell growth and protein synthesis, providing the mechanistic rationale for its clinical investigation in advanced solid tumors, non-small cell lung carcinoma, renal cell carcinoma, and neuroendocrine tumors.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).